Translate Bio Receives FDA Fast Track Designation for MRT5005 for the Treatment of Cystic Fibrosis
February 26, 2020 07:30 ET
|
Translate Bio, Inc.
-- First inhaled mRNA therapeutic remains on track to report results from its ongoing multiple-ascending dose (MAD) portion of Phase 1/2 clinical trial in the third quarter of 2020 -- LEXINGTON,...
Aldevron Adds DasherGFP® mRNA to its Product Portfolio
February 12, 2020 10:30 ET
|
Aldevron
Fargo, N.D., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins, mRNA and antibodies for the biotech industry, announced...
BioNTech plant öffentliches Angebot von American Depository Shares
February 03, 2020 16:46 ET
|
BioNTech SE
MAINZ, Deutschland, Feb. 03, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) hat heute die Registrierungsdokumente (Form F-1) bei der amerikanischen...
BioNTech Announces Commencement of Public Offering of American Depositary Shares
February 03, 2020 16:46 ET
|
BioNTech SE
MAINZ, Germany, Feb. 03, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today, that it has filed a registration statement on Form F-1 with the United...
CureVac berichtet positive Ergebnisse aus niedrig dosierter 1 µg Phase-1-Studie mit Tollwut-Impfstoff
January 07, 2020 07:00 ET
|
CureVac AG
Impfung induziert selbst bei niedriger Dosierung bei sämtlichen Probanden eine Immunantwort und ist gut verträglich Klinische Ergebnisse unterstreichen Potenzial von CureVacs...
CureVac Announces Positive Results in Low Dose – 1 µg – Rabies Vaccine Clinical Phase 1 Study
January 07, 2020 07:00 ET
|
CureVac AG
Low dose vaccination induced immune response in all subjects and was well tolerated Clinical results underline potency of CureVac’s technology platform Detailed results to be presented at an upcoming...
Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
December 19, 2019 11:05 ET
|
CureVac AG
Company Announcement Genmab and CureVac enter broad strategic partnership Companies to conduct joint research on first program; option for Genmab to initiate three additional programs during 5-year...
BioNTech präsentiert auf der 38. Annual J.P. Morgan Healthcare Conference
December 18, 2019 09:30 ET
|
BioNTech SE
MAINZ, Deutschland, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX) gab heute bekannt, dass CEO und Mitbegründer Prof. Dr. Ugur Sahin die Firma auf der 38. Annual J.P. Morgan Healthcare...
BioNTech to Present at the 38th Annual J.P. Morgan Healthcare Conference
December 18, 2019 09:30 ET
|
BioNTech SE
MAINZ, Germany, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ: BNTX) today announced that CEO and Co-founder Ugur Sahin, MD, will present at the 38th Annual J.P. Morgan Healthcare Conference...
Europäische Investmentbank gewährt BioNTech 50 Millionen Euro-Finanzierung im Rahmen der Investmentoffensive für Europa
December 17, 2019 07:00 ET
|
BioNTech SE
Gelder unterstützen BioNTechs Forschung und Entwicklung zur KrebsbehandlungFinanzierung wird im Rahmen der Investitionsoffensive für Europa, oder Juncker-Plan, zur Verfügung gestellt LUXEMBOURG und...